IN8bio (INAB) vs Niki BioSolutions (NIKI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
IN8bio (INAB) has outperformed Niki BioSolutions (NIKI) over the past year, losing 42.7% versus a loss of 82.1%. Over five years, NIKI leads with a -98.3% price change compared with -99.2% for INAB. IN8bio is the larger company by market cap ($13.4 million vs $13.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | INAB | NIKI |
|---|---|---|
| Share price | $1.36 | $4.26 |
| Market cap | $13.36M | $13.28M |
| 1-day change | -1.81% | -1.39% |
| YTD return | -41.03% | -59.25% |
| 1-year return | -42.74% | -82.07% |
| 5-year return | -99.23% | -98.33% |
| EPS (TTM) | $-1.62 | $-2.90 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.73 | $24.00 |
| 52-week low | $0.88 | $4.10 |
| Distance from 52-week high | -50.37% | -82.25% |
| Analyst consensus | none | — |
| Avg. price target upside | +416.61% | — |
| Average volume | 58.36K | 157.52K |
| Shares outstanding | 9.86M | 2.94M |
| Employees | 18 | 1 |
| Sector | Health Care | Industrials |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Industrial Machinery/Components |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- INAB has outperformed NIKI by 39.3 percentage points over the past year.
- The two companies sit in different sectors: IN8bio in Health Care and Niki BioSolutions in Industrials.
About IN8bio
INAB stock →IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with hematologic malignancies undergoing hematopoietic stem cell transplantation.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 18 employees
About Niki BioSolutions
NIKI stock →Niki BioSolutions, Inc., through its subsidiaries, operates as a clinical-stage biopharmaceutical company and engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in a Phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small molecule, which is in a Phase 1 clinical trial for the treatment of bacterial infections, such as staphylococcus aureus, mycobacterium tuberculosis, and pseudomonas aeruginosa.
Industrials · Industrial Machinery/Components · 1 employees
INAB vs NIKI FAQ
Which is bigger, IN8bio or Niki BioSolutions?
IN8bio (INAB) is larger, with a market capitalization of $13.36M compared with $13.28M for Niki BioSolutions (NIKI).
Which stock has performed better over the past year, INAB or NIKI?
INAB returned -42.74% over the past 12 months, compared with -82.07% for NIKI (price return, excluding dividends). Past performance does not predict future results.
Are IN8bio and Niki BioSolutions in the same industry?
No. IN8bio is in the Health Care sector, while Niki BioSolutions is in Industrials.